Serum T3 Level and Duration of Minimum Maintenance Dose Therapy Predict Relapse n Methimazole-Treated Graves Disease.

ABSTRACT:

Background

Methimazole (MMI) has been advocated as a preferred option for most Graves disease (GD) patients. However, long-term remission after a course of MMI treatment is achieved in only 20% to 40% of patients, depending on the duration of follow-up.

Objective

To evaluate clinical factors for predicting relapse of GD in Thai patients after MMI treatment.

Methods

A retrospective analysis was performed of newly diagnosed patients with GD who achieved remission of hyperthyroid GD after at least 12 months of MMI treatment. Long-term outcomes were assessed and predictive factors of early and late relapse were evaluated.

Results

A total of 443 patients with newly diagnosed GD who were treated with MMI for at least 12 months from 1985 to 2019, and were able to disc

SUBMITTER: Thewjitcharoen Y 

PROVIDER: S-EPMC7716657 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature